Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea

Phase 2

Terminated

Conditions: Huntington's Disease
Chorea

Interventions: Drug: AFQ056
Drug: Placebo

First Posted Date: 2009-11-25

Last Posted Date: 2011-09-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 44

Registration Number: NCT01019473

Locations: 🇬🇧
Novartis Investigator Site, Oxford, United Kingdom

Everolimus in de Novo Heart Transplant Recipients

Phase 4

Completed

Conditions: Cardiac Transplantation

Interventions: Drug: Mycophenolate mofetil + Everolimus
Drug: Everolimus

First Posted Date: 2009-11-20

Last Posted Date: 2015-01-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 182

Registration Number: NCT01017029

Locations: 🇮🇹
Novartis Investigative Site, Napoli, Italy

Lapatinib in Combination With Vinorelbine

Phase 2

Completed

Conditions: Cancer

Interventions: Drug: Lapatinib
Drug: Vinorelbine
Drug: Capecitabine

First Posted Date: 2009-11-16

Last Posted Date: 2017-05-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 112

Registration Number: NCT01013740

Locations: 🇪🇸
Novartis Investigative Site, Zamora, Spain

Effect of Indacaterol on Inspiratory Capacity (IC)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Indacaterol
Drug: Tiotropium
Drug: Placebo

First Posted Date: 2009-11-13

Last Posted Date: 2016-02-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 173

Registration Number: NCT01012765

Locations: 🇩🇪
Novartis Investigative site, Leipzig, Germany
🇩🇪
Novartis Investigative Site, Zerbst, Germany
🇩🇪
Novartis Investigator Site, Witten, Germany

Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Indacaterol 150 μg via the Concept1 dry-powder inhaler
Drug: Indacaterol 60 μg via the Simoon dry-powder inhaler
Drug: Indacaterol 120 μg via the Simoon dry-powder inhaler
Drug: Placebo to indacaterol via the Concept1 dry-powder inhaler

First Posted Date: 2009-11-13

Last Posted Date: 2011-08-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 35

Registration Number: NCT01012739

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease

Phase 2

Terminated

Conditions: Crohn's Disease
Inflammatory Bowel Disease

Interventions: Drug: AIN457

First Posted Date: 2009-11-06

Last Posted Date: 2021-07-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 7

Registration Number: NCT01009281

Locations: 🇺🇸
Mount Sinai, One Gustave L. Levy Place, Box 1118, New York, New York, United States
🇺🇸
Wake Research Asspcoates. ::C. 3100 Duraleigh Road, Suite 304, Raleigh, North Carolina, United States
🇺🇸
Conneticut Gastroenterology Institute, 39 Brewster Road, Bristol, Connecticut, United States

and more 2 locations

Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: LBH589

First Posted Date: 2009-11-05

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 25

Registration Number: NCT01007968

Locations: 🇺🇸
University of Utah / Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇬🇧
Novartis Investigative Site, Edinburgh, United Kingdom

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Phase 3

Completed

Conditions: Metastatic Breast Cancer
HER2/Neu Over-expressing Locally Advanced Breast Cancer

Interventions: Drug: Placebo
Drug: everolimus
Drug: vinorelbine
Drug: trastuzumab

First Posted Date: 2009-11-04

Last Posted Date: 2017-04-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 569

Registration Number: NCT01007942

Locations: 🇺🇸
University of Arizona / Cancer Center AZ Onc Assoc, Tucson, Arizona, United States
🇺🇸
Florida Cancer Specialists DeptofFloridaCancerSpecialists, Fort Myers, Florida, United States
🇺🇸
Memorial Hospital Memorial Cancer Institute, Hollywood, Florida, United States

and more 41 locations

Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: omalizumab

First Posted Date: 2009-11-03

Last Posted Date: 2012-07-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 79

Registration Number: NCT01007149

Locations: 🇫🇷
Novartis Investigative Site, Toulouse, France

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Phase 1

Completed

Conditions: Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3
Squamous Lung Cancer With FGFR1 Amplification
Bladder Cancer With FGFR3 Mutation or Fusion
Advanced Solid Tumors With FGFR1 Amplication
Advanced Solid Tumors With FGFR2 Amplication
Advanced Solid Tumors With FGFR3 Mutation

Interventions: Drug: BGJ398

First Posted Date: 2009-10-29

Last Posted Date: 2019-10-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 208

Registration Number: NCT01004224

Locations: 🇺🇸
Thomas Jefferson University Hospital Onc Dept, Philadelphia, Pennsylvania, United States
🇹🇷
Novartis Investigative Site, Izmir, Turkey
🇺🇸
University of Colorado Dept. of Anschutz Cancer (3), Aurora, Colorado, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy